Loading
AI-081 is an experimental bispecific antibody from OncoC4 in phase 2 trials, aimed at PD-1 and VEGF / VEGFR.
AI-081 is a bispecific antibody developed by OncoC4. Its targets are PD-1 and VEGF / VEGFR (the sponsor names PD-1/VEGF). The sponsor states: dual checkpoint and angiogenesis inhibition. ClinicalTrials.gov describes the intervention as: AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06635785, plans to enrol 387 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
dual checkpoint and angiogenesis inhibition. Connects to PD-1 and VEGF / VEGFR.
1.One arm of AI-081 binds PD-1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AI-081" OR ABSTRACT:"AI-081" OR TITLE:"Bispecific anti-PD-1/VEGF" OR ABSTRACT:"Bispecific anti-PD-1/VEGF") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AI-081, not a curated reading list.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.